HerculeBaditt

Equity Analyst - Industrials, Healthcare, Consumer

[HerculeBaditt @HerculeBaditt]

Four of the five biggest UK market share gainers YTD are Chinese brands most Europeans couldn't name two years ago. Winning on value European OEMs can't structurally match. Hard not to see them winning everywhere tariffs don't block them. $VOW $STLA $BMW

[HerculeBaditt @HerculeBaditt]

Chinese consumers are no longer treating domestic brands as inferior substitutes, which fundamentally undermines the brand premium and pricing power that Porsche depends upon.

[HerculeBaditt @HerculeBaditt]

Hard to see how $P911 ever regains the Chinese market; China is still 10-15% of revenue today.

[HerculeBaditt @HerculeBaditt]

Cumulative number of objects launched into space growing exponentially, with a large investable universe of companies levered to the space economy standing to benefit

[HerculeBaditt @HerculeBaditt]

@TheLAPurchaser Also a lot of pharma CapEx previously frozen pending U.S. healthcare policy clarity now thawing. Some of that incremental spend should flow into bioprocessing equipment which is the main missing piece of the recovery.

[HerculeBaditt @HerculeBaditt]

@_invaro From IQV's 10-K

[HerculeBaditt @HerculeBaditt]

Statistical programming + data management = 20-30% of total clinical trial costs, still widely outsourced today. Most actionable targets for AI displacement within CRO and corresponding internalization by large pharma. $IQV, $TMO, $ICLR

[HerculeBaditt @HerculeBaditt]

@bscholl @boomsupersonic Awesome @bscholl ! Are you still targeting Overture entry into service around 2029 and what are the main limiting factors to get there?

[HerculeBaditt @HerculeBaditt]

@b_cap21 U.S. regulated utilities good way to play these differences. $AEP well positioned with 40% of CapEx plan in Texas/Ohio.

[HerculeBaditt @HerculeBaditt]

@negligible_cap With majority of premium sitting in assumed multiple expansion. Market not convinced $UMG is worth 25x NTM P/E.

[HerculeBaditt @HerculeBaditt]

@Divergent7651 Not sure about Automation but I think Aero should trade at discount to peers despite higher margins with recurring OE pricing pressures (2016, 2017, 2021, 2024), having to incentivize airframers to secure competitive positions. Biz jet exposure also lower quality/growth.

[HerculeBaditt @HerculeBaditt]

@FundamentEdge AI lets you cover more ideas in the same amount of time. Assuming constant hit rate and slugging ratio, more ideas mathematically translate into higher returns.

[HerculeBaditt @HerculeBaditt]

Lots of small players deep down the aerospace supply chain which stand to benefit enormously from the continuous supply-demand mismatch. For example, $FTAI on the aftermarket-side or $CRS on the OEM-side.

[HerculeBaditt @HerculeBaditt]

$CTLT on the rise of the CDMO and how it enabled independent biotechs to decentralize the industry. Share of drugs pipeline from top 25 biopharma dropped from ~45% in the early 90s to ~8% today.

[HerculeBaditt @HerculeBaditt]

@PedroPURocha @DanielSLoeb1 Here you go - https://t.co/B8JKsMRPkT

[HerculeBaditt @HerculeBaditt]

@PhanLawyers @Quantumup1 (1) Creates a scalable ecosystem of compatible/modular products across workflows (think Apple ecosystem as an analogy); (2) Customers need to focus money/time/brainpower on one thing and one thing only: innovating, having a trusted fully-integrated turnkey solution enables that.

[HerculeBaditt @HerculeBaditt]

@stumvc007 @lhamtil @Teemacsj Strong ending - "Not only is this a great merger, this is a necessary combination for the good of mankind, for the good of the Free World."

[HerculeBaditt @HerculeBaditt]

@JerryCap If we get down to the most important thing for $DHR, which is getting a deep understanding of DBS, the 2 following reads are real game-changers:
https://t.co/HL9FOqJral
https://t.co/EUIAV4MGax

[HerculeBaditt @HerculeBaditt]

@LatereJp $DHR Investor Day 2022 presentation - https://t.co/4ySegLonx5

[HerculeBaditt @HerculeBaditt]

Drug market remains 80% small molecules / 20% biologics today, but the biologic era is just getting started (60% of all drugs in development are biologics, >20K biologics currently in R&D pipeline vs ~500 FDA approved today).

[HerculeBaditt @HerculeBaditt]

Animal pharma steers clear of most of the drawbacks that human pharma suffers from. Among others, it doesn’t depend on one species (humans) but 8. $ZTS